Upregulating substance P levels to treat obstructive sleep apnea

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.12, Iss.5, 2008-05, pp. : 583-588

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacotherapy of obstructive sleep apnea

By Lin Chia Mo Huang Yu Shu Guilleminault Christian

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 841-857

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological Treatment of Obstructive Sleep Apnea

Current Pharmaceutical Design, Vol. 17, Iss. 15, 2011-05 ,pp. : 1418-1425

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea

Current Pharmaceutical Design, Vol. 14, Iss. 32, 2008-11 ,pp. : 3466-3473

Bentham Science Publishers

Access to resources Recommend Favorite

Obstructive Sleep Apnea: What Does the Cardiovascular Physician Need to Know?

By Nancy A. Collop

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 2, 2005-01 ,pp. : 71-81

Adis International

Access to resources Recommend Favorite

Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 12, Iss. 5, 2013-01 ,pp. : 362-367

Bentham Science Publishers

Access to resources Recommend Favorite